Join Growin Stock Community!

博錸6572.TW Overview

TW StockBiotech. & Medical
(No presentation for 6572)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

博錸（6572）Overall Performance

博錸（6572）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

博錸（6572） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

博錸（6572）Key Information

博錸（6572）Profile

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation extraction kits; IntelliPlex platform that is designed for pCode technology with for sample-to-answer multiplexing assays; oncology kits for lung cancer and mutation detection, as well as rearrangements; IntelliPlex SARS-CoV-2 detection test kits/flu kits and IntelliPlex SARS-CoV-2 variant analysis kits; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.

博錸（6572）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.59
PB Ratio
2.53
Price-to-FCF
6.08
METRIC
VALUE
vs. INDUSTRY
Gross Margin
34.86%
Net Margin
-38.42%
Revenue Growth (YoY)
1.30%
Profit Growth (YoY)
14.44%
3-Year Revenue Growth
-2.37%
3-Year Profit Growth
73.09%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.19
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.59
PB Ratio
2.53
Price-to-FCF
6.08
Gross Margin
34.86%
Net Margin
-38.42%
Revenue Growth (YoY)
1.30%
Profit Growth (YoY)
14.44%
3-Year Revenue Growth
-2.37%
3-Year Profit Growth
73.09%
default symbol

6572

博錸

8.00D

-4.25%

(-0.04)

  • When is 6572's latest earnings report released?

    The most recent financial report for 博錸 (6572) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6572's short-term business performance and financial health. For the latest updates on 6572's earnings releases, visit this page regularly.

  • How much cash does 6572 have?

    At the end of the period, 博錸 (6572) held Total Cash and Cash Equivalents of 195.38M, accounting for 0.37 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6572 go with three margins increasing?

    In the latest report, 博錸 (6572) did not achieve the “three margins increasing” benchmark, with a gross margin of 31.98%%, operating margin of -60.18%%, and net margin of -74.82%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6572's profit trajectory and future growth potential.